Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 1

Interventions

Fluorouracil 126Leucovorin 90Oxaliplatin 82Specimen Handling 71Gemcitabine 61Magnetic Resonance Spectroscopy 55Irinotecan 55Biopsy 53Capecitabine 40Bevacizumab 40Radiotherapy 37Cisplatin 34Cetuximab 29Chemotherapy, Adjuvant 28Erlotinib Hydrochloride 26Neoadjuvant Therapy 21dehydroftorafur 20Cyclophosphamide 19Nivolumab 18Sorafenib 17Radiation 17Paclitaxel 17X-Rays 16Doxorubicin 16aldesleukin 14Immunoglobulin G 14Disulfides 14fludarabine 13Folfox protocol 13Carboplatin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × CX 5461 × Gastrointestinal × Clear all
NCT07147231 2026-05-13

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
86 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡